Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531022 | 0.83 | GAA (0.41) | PAX8MT-CO2KMT2ADGAT1MAPT | |
| SCHEMBL17166912 | 0.83 | SSTR4 (0.36) | HDAC1HDAC6PAX8MT-CO2USP30 | |
| SCHEMBL5241743 | 0.82 | F2 (0.38) | NPSR1SLC22A12TSHR | |
| SCHEMBL3634800 | 0.82 | MLYCD (0.40) | HDAC1HDAC6KMT2AMAPTTSHR | |
| SCHEMBL19470169 | 0.80 | TRPA1 (0.34) | HDAC1HDAC6PAX8MT-CO2USP30 | |
| SCHEMBL23168280 | 0.79 | MAPK1 (0.54) | NPSR1KMT2AMAPTMEN1CYP1A2 | |
| SCHEMBL2033422 | 0.79 | HDAC1 (0.37) | HDAC1HDAC6PAX8MT-CO2USP30 | |
| SCHEMBL4039542 | 0.79 | P4HTM (0.36) | HDAC1HDAC6PAX8MT-CO2USP30 | |
| SCHEMBL15932872 | 0.79 | CYP1A2 (0.44) | MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL9571667 | 0.77 | RAB9A (0.45) | KMT2ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| CN-107406429-B | Pyridazinone derivatives and their use in the treatment of cancer | 基因泰克公司 | 2021-07-06 | — | — | CN | disclosed |
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239861-B2 | Therapeutic compounds and uses thereof | GENETECH, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3242874-B1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| EP-3242874-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016112298-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2016-07-14 | — | — | WO | disclosed |
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | HDAC1 1897/4885HDAC6 951/4885NPSR1 3112/4885 |
| US-10239861-B2 | Therapeutic compounds and uses thereof | HDAC10, HDAC6, HDAC11 | HDAC1 5/4885HDAC6 2/4885NPSR1 1852/4885 |
| US-20180037566-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | HDAC10, HDAC6, HDAC11 | HDAC1 5/4885HDAC6 2/4885NPSR1 1852/4885 |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | HDAC1 486/4885HDAC6 636/4885NPSR1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.